Cold Agglutinin Disease Drugs Market is segmented By Treatment Approach (Rituximab monotherapy, Corticosteroids, Biologics like ENJAYMO), By Pipeline Drugs (Iptacopan, Parsaclisib, Pegcetacoplan), By Type of Disease (Primary Cold Agglutinin Disease, Secondary Cold Agglutinin Disease), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Million) for the above-mentioned segments.
Market Size in USD
CAGR22.6%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 22.6% |
Market Concentration | Medium |
Major Players | Sanofi, Novartis, Incyte Corporation, Apellis Pharmaceuticals, Sobi |
The cold agglutinin disease drugs market is estimated to be valued at USD 134 Mn in 2024 and is expected to reach USD 558 Mn by 2031, growing at a compound annual growth rate (CAGR) of 22.6% from 2024 to 2031.
Factors such as the rising prevalence of cold agglutinin disease, growing awareness about the disease, and increasing research and development activities for novel treatment options are expected to drive the demand for cold agglutinin disease drugs during the forecast period.